Prashanth R Vennalaganti1, Vivek Kaul2, Kenneth K Wang3, Gary W Falk4, Nicholas J Shaheen5, Anthony Infantolino6, David A Johnson7, Glenn Eisen8, Lauren B Gerson8, Michael S Smith9, Prasad G Iyer3, Charles J Lightdale10, Felice Schnoll-Sussman11, Neil Gupta12, Seth A Gross13, Julian Abrams10, Gregory B Haber13, Ram Chuttani14, Douglas K Pleskow14, Shivangi Kothari2, John R Goldblum15, Yaxia Zhang15, Prateek Sharma16. 1. Department of Gastroenterology and Hepatology, Veterans Affairs Medical Center, Kansas City, Missouri, USA; Department of Gastroenterology, University of Kansas School of Medicine, Kansas City, Kansas, USA. 2. Department of Gastroenterology, University of Rochester, Rochester, New York, USA. 3. Department of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 5. Department of Gastroenterology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 6. Department of Gastroenterology, Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania, USA. 7. Department of Gastroenterology, Eastern VA Medical School, Norfolk, Virginia, USA. 8. Department of Gastroenterology, Stanford University, Palo Alto, California, USA. 9. Department of Gastroenterology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA. 10. Department of Gastroenterology, Columbia University school of Medicine, New York, New York, USA. 11. Department of Gastroenterology, Weill Cornell Medical Center, New York, New York, USA. 12. Department of Gastroenterology, Loyola University Medical Center, Maywood, Illinois, USA. 13. Department of Gastroenterology, New York City Langone Medical Center, New York, New York, USA. 14. Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 15. Department of Anatomical Pathology, Cleveland Clinic, Cleveland, Ohio, USA. 16. Department of Gastroenterology and Hepatology, Veterans Affairs Medical Center, Kansas City, Missouri, USA; Department of Gastroenterology, University of Kansas School of Medicine, Kansas City, Kansas, USA. Electronic address: psharma@kumc.edu.
Abstract
BACKGROUND AND AIMS: Wide-area transepithelial sampling (WATS) with computer-assisted 3-dimensional analysis is a sampling technique that combines abrasive brushing of the Barrett's esophagus (BE) mucosa followed by neural network analysis to highlight abnormal-appearing cells. METHODS: We performed a randomized trial of referred BE patients undergoing surveillance at 16 medical centers. Subjects received either biopsy sampling followed by WATS or WATS followed by biopsy sampling. The primary outcome was rate of detection of high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC) using WATS in conjunction with biopsy sampling compared with biopsy sampling alone using standard histopathologic criteria. Secondary aims included evaluating neoplasia detection rates based on the procedure order (WATS vs biopsy sampling first), of each procedure separately, and the additional time required for WATS. RESULTS:One hundred sixty patients (mean age, 63.4 years; 76% men; 95% white) completed the trial. The median circumferential and maximal BE extents were 1.0 cm (interquartile range: .0-5.0) and 4.0 cm (interquartile range, 2.0-8.0), respectively. The diagnostic yield for biopsy sampling alone was as follows: HGD/EAC, 7 (4.4%); low-grade dysplasia (LGD), 28 (17.5%); nondysplastic BE (NDBE), 106 (66.25%); and no BE, 19 (11.9%). The addition of WATS to biopsy sampling yielded an additional 23 cases of HGD/EAC (absolute increase, 14.4%; 95% confidence interval, 7.5%-21.2%). Among these 23 patients, 11 were classified by biopsy sampling as NDBE and 12 as LGD/indefinite for dysplasia (IND); 14 received biopsy sampling first and 9 WATS first (not significant) and most (n = 21; 91.7%) had a prior dysplasia history. WATS added an average of 4.5 minutes to the procedure. CONCLUSION: Results of this multicenter, prospective, randomized trial demonstrate that the use of WATS in a referral BE population increases the detection of HGD/EAC. (Clinical trial registration number: NCT03008980.).
RCT Entities:
BACKGROUND AND AIMS: Wide-area transepithelial sampling (WATS) with computer-assisted 3-dimensional analysis is a sampling technique that combines abrasive brushing of the Barrett's esophagus (BE) mucosa followed by neural network analysis to highlight abnormal-appearing cells. METHODS: We performed a randomized trial of referred BE patients undergoing surveillance at 16 medical centers. Subjects received either biopsy sampling followed by WATS or WATS followed by biopsy sampling. The primary outcome was rate of detection of high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC) using WATS in conjunction with biopsy sampling compared with biopsy sampling alone using standard histopathologic criteria. Secondary aims included evaluating neoplasia detection rates based on the procedure order (WATS vs biopsy sampling first), of each procedure separately, and the additional time required for WATS. RESULTS: One hundred sixty patients (mean age, 63.4 years; 76% men; 95% white) completed the trial. The median circumferential and maximal BE extents were 1.0 cm (interquartile range: .0-5.0) and 4.0 cm (interquartile range, 2.0-8.0), respectively. The diagnostic yield for biopsy sampling alone was as follows: HGD/EAC, 7 (4.4%); low-grade dysplasia (LGD), 28 (17.5%); nondysplastic BE (NDBE), 106 (66.25%); and no BE, 19 (11.9%). The addition of WATS to biopsy sampling yielded an additional 23 cases of HGD/EAC (absolute increase, 14.4%; 95% confidence interval, 7.5%-21.2%). Among these 23 patients, 11 were classified by biopsy sampling as NDBE and 12 as LGD/indefinite for dysplasia (IND); 14 received biopsy sampling first and 9 WATS first (not significant) and most (n = 21; 91.7%) had a prior dysplasia history. WATS added an average of 4.5 minutes to the procedure. CONCLUSION: Results of this multicenter, prospective, randomized trial demonstrate that the use of WATS in a referral BE population increases the detection of HGD/EAC. (Clinical trial registration number: NCT03008980.).
Authors: Mazen R Al-Mansour; Antonio Caycedo-Marulanda; Brian R Davis; Abdulrahim Alawashez; Salvatore Docimo; Alia Qureshi; Shawn Tsuda Journal: Surg Endosc Date: 2020-05-13 Impact factor: 4.584
Authors: Jorge D Machicado; Samuel Han; Rena H Yadlapati; Violette C Simon; Bashar J Qumseya; Shahnaz Sultan; Vladimir M Kushnir; Sri Komanduri; Amit Rastogi; V Raman Muthusamy; Rehan Haidry; Krish Ragunath; Rajvinder Singh; Hazem T Hammad; Nicholas J Shaheen; Sachin Wani Journal: Dig Dis Sci Date: 2018-09-03 Impact factor: 3.199
Authors: D Chamil Codipilly; Apoorva Krishna Chandar; Kenneth K Wang; David A Katzka; John R Goldblum; Prashanthi N Thota; Gary W Falk; Amitabh Chak; Prasad G Iyer Journal: Gastrointest Endosc Date: 2021-09-17 Impact factor: 9.427
Authors: Yasmine Hussein Agha; Sachin Srinivasan; Jeffrey Hyder; Chelsea Wuthnow; Ali Taleb; Nathan Tofteland; William Kilgore; William Salyers Journal: Ann Gastroenterol Date: 2020-12-07